AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37212312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual contacts of mpox cases
Number of subjects: 25
Study 37212315 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT04 (ustekinumab candidate biosimilar)
Number of subjects: 0
Study 37212315 — intervention group
Group type: COMPARATOR
Intervention: Reference product (RP) ustekinumab (EU-approved and US-licensed Stelara®)
Number of subjects: 0
Study 37212315 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatment arms (AVT04, US-RP, EU-RP)
Number of subjects: 0
Study 37212440 — intervention group
Group type: EXPERIMENTAL
Intervention: NI006
Number of subjects: 40
Study 37212440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 37212442 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber leadless pacemaker system
Number of subjects: 300
Study 37212600 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 2859
Study 37212600 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 2859
Study 37212651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (25-100 mg)
Number of subjects: 184
Study 37212651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 37212651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 184
Study 37212686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus S-1 combined intraperitoneal and intravenous paclitaxel
Number of subjects: 36
Study 37212760 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline intervention
Number of subjects: 504
Study 37212760 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment fee item intervention
Number of subjects: 504
Study 37212796 — intervention group
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan (HER3-DXd)
Number of subjects: 0
Study 37212825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine-gynx
Number of subjects: 104
Study 37212970 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy lifting strength training (HLST) program, 12 weeks, twice weekly, lifting 80-90% of 1 repetition maximum (1RM)
Number of subjects: 9
Study 37213005 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 837
Study 37213005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 837
Study 37213005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 837
Study 37213030 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Number of subjects: 507
Study 37213030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 37213048 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 10×1-min intervals ≥90% maximum heart rate
Number of subjects: 15
Study 37213048 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 15
Study 37213102 — intervention group
Group type: EXPERIMENTAL
Intervention: Danuglipron 120 mg twice daily
Number of subjects: 411
Study 37213102 — intervention group
Group type: EXPERIMENTAL
Intervention: Danuglipron 80 mg twice daily
Number of subjects: 411
Study 37213102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 37213109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 5047
Study 37213109 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 5047
Study 37213109 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 5047
Study 37213109 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 5047
Study 37213122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual thrombolytic treatment with 5 mg intravenous alteplase and 40 mg intravenous mutant prourokinase
Number of subjects: 238
Study 37213122 — intervention group
Group type: COMPARATOR
Intervention: Usual care with 0.9 mg/kg intravenous alteplase
Number of subjects: 238
Study 37213187 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT program (intervention) includes predischarge kidney health education from nurses and coordinated postdischarge laboratory monitoring (serum creatinine and urine protein assessment) and follow-up with a primary care provider and pharmacist within 14 days.
Number of subjects: 34
Study 37213187 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) receives no specific study-related intervention, with AKI care at the direction of the treating team.
Number of subjects: 34
Study 37213187 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT program (intervention)
Number of subjects: 34
Study 37213187 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 34
Study 37213195 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized content in a tailored style (PT) + usual care (UC)
Number of subjects: 169
Study 37213195 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized content in a nontailored style (PN) + usual care (UC)
Number of subjects: 169
Study 37213195 — intervention group
Group type: COMPARATOR
Intervention: Personalized content in a tailored style (PT)
Number of subjects: 169
Study 37213195 — intervention group
Group type: COMPARATOR
Intervention: Personalized content in a nontailored style (PN)
Number of subjects: 169
Study 37213481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) at 150 to 200 kHz
Number of subjects: 4
Study 37213481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields)
Number of subjects: 4
Study 37213661 — intervention group
Group type: EXPERIMENTAL
Intervention: Subchondroplasty (SCP)
Number of subjects: 50
Study 37213724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-visit educational video and pamphlet
Number of subjects: 0
Study 37213724 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet alone
Number of subjects: 0
Study 37213900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical superficial siderosis (cSS) present
Number of subjects: 673
Study 37213900 — intervention group
Group type: EXPERIMENTAL
Intervention: Large hematoma volume
Number of subjects: 673
Study 37213900 — intervention group
Group type: EXPERIMENTAL
Intervention: cSS
Number of subjects: 673
Study 37213907 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic Network Targeting Field (ENTF) therapy
Number of subjects: 344
Study 37213907 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 344
Study 37213913 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely supervised transcranial direct current stimulation (RS-tDCS)
Number of subjects: 25
Study 37213913 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 25
Study 37214171 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 37214171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37214210 — intervention group
Group type: EXPERIMENTAL
Intervention: MALT1 inhibitor
Number of subjects: 0
Study 37214431 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous DL-beta-hydroxybutyrate supplementation, dosage and duration not specified.
Number of subjects: 0
Study 37214431 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not specified.
Number of subjects: 0
Study 37214450 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan-containing triple therapy
Number of subjects: 0
Study 37214806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Observational Cohort Study
Number of subjects: 0
Study 37214806 — intervention group
Group type: EXPERIMENTAL
Intervention: Data and biosamples collection
Number of subjects: 0
Study 37214840 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated group
Number of subjects: 0
Study 37214840 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study 37214890 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based and community-driven intervention to reduce gun violence, details on dosage and duration not available.
Number of subjects: 0
Study 37214890 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details on intervention not available.
Number of subjects: 0
Study 37214968 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 30000
Study 37214968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30000
Study 37215108 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR T cells overexpressing c-Jun
Number of subjects: 0
Study 37215108 — intervention group
Group type: COMPARATOR
Intervention: HLA-A2/AFP TCR
Number of subjects: 0
Study 37215110 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab plus chemotherapy
Number of subjects: 0
Study 37215110 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 37215141 — intervention group
Group type: EXPERIMENTAL
Intervention: Exome sequencing (ES)
Number of subjects: 332
Study 37215141 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal microarray analysis (CMA)
Number of subjects: 332
Study 37215141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined approach of ES and CMA
Number of subjects: 332
Study 37215348 — intervention group
Group type: EXPERIMENTAL
Intervention: VACStent
Number of subjects: 50
Study 37215389 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prucalopride (0.04 mg/kg)
Number of subjects: 240
Study 37215389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prucalopride (0.08 mg/kg)
Number of subjects: 240
Study 37215389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 37215391 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (NSPT)
Number of subjects: 40
Study 37215551 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic concordance approach
Number of subjects: 282
Study 37215644 — intervention group
Group type: EXPERIMENTAL
Intervention: Community gardening (receiving a community garden plot, plants and seeds, and a gardening class)
Number of subjects: 0
Study 37215644 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist for a community garden plot)
Number of subjects: 0
Study 37215679 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Violent Resistance (NVR) program, a 10-session parental-group intervention
Number of subjects: 82
Study 37215679 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU), supportive counseling and psychoeducation
Number of subjects: 82
Study 37215725 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP1815
Number of subjects: 0
Study 37215725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37215727 — intervention group
Group type: EXPERIMENTAL
Intervention: Presepsin:gelsolin (PSEP:GSN) ratio
Number of subjects: 126
Study 37215727 — intervention group
Group type: COMPARATOR
Intervention: Routine lab and clinical parameters
Number of subjects: 126
Study 37215727 — intervention group
Group type: EXPERIMENTAL
Intervention: PSEP:GSN ratio
Number of subjects: 126
Study 37216212 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tissue reconstruction (ATR, n = 127)
Number of subjects: 1651
Study 37216212 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-based reconstruction (IBR, n = 60)
Number of subjects: 1651
Study 37216212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined autologous tissue and implant reconstruction (n = 60)
Number of subjects: 1651
Study 37216212 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reconstruction (IR)
Number of subjects: 1651
Study 37216212 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy only
Number of subjects: 1651
Study 37216230 — intervention group
Group type: EXPERIMENTAL
Intervention: MTCN+ model
Number of subjects: 363
Study 37216230 — intervention group
Group type: COMPARATOR
Intervention: MTCN model
Number of subjects: 363
Study 37216230 — intervention group
Group type: COMPARATOR
Intervention: Artificial model
Number of subjects: 363
Study 37216230 — intervention group
Group type: EXPERIMENTAL
Intervention: MTCN+ model in small primary tumors
Number of subjects: 363
Study 37216357 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term antibiotic treatment (8 weeks in early IOM and 12 weeks in delayed IOM)
Number of subjects: 364
Study 37216357 — intervention group
Group type: COMPARATOR
Intervention: Long-term antibiotic treatment (12 weeks in early IOM or until fracture healing or implant removal in delayed IOM)
Number of subjects: 364
Study 37216357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both short-term and long-term treatments
Number of subjects: 364
Study 37216396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib (20 mg/kg) combined with Ara-C (100 mg/m2 every 12 h, days 1-5) and 2-CdA (6 mg/m2 per day, days 1-5) followed by mono 2-CdA.
Number of subjects: 19
Study 37216921 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinecerfont (50 mg twice daily for 14 days)
Number of subjects: 8
Study 37217137 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral Buckle (SB)
Number of subjects: 91
Study 37217137 — intervention group
Group type: COMPARATOR
Intervention: Pars Plana Vitrectomy with Scleral Buckle (PPV-SB)
Number of subjects: 91
Study 37217137 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral Buckle (SB) with external subretinal fluid drainage
Number of subjects: 91
Study 37217137 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral Buckle (SB) without external subretinal fluid drainage
Number of subjects: 91
Study 37217137 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral Buckle (SB) and Pars Plana Vitrectomy with Scleral Buckle (PPV-SB)
Number of subjects: 91
Study 37217137 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal displacement
Number of subjects: 91
Study 37217183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) therapy
Number of subjects: 25
Study 37217188 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity care (HIC) strategy
Number of subjects: 1077
Study 37217188 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1077
Study 37217243 — intervention group
Group type: EXPERIMENTAL
Intervention: IDO/PD-L1 targeting peptide vaccine combined with nivolumab (NCT03047928)
Number of subjects: 30
Study 37217243 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients in cohort B receiving anti-PD-1 therapy with peptide vaccine)
Number of subjects: 30
Study 37217263 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in France
Number of subjects: 20012
Study 37217263 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in Germany
Number of subjects: 20012
Study 37217263 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in Italy
Number of subjects: 20012
Study 37217263 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in Japan
Number of subjects: 20012
Study 37217263 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in US Explorys database
Number of subjects: 20012
Study 37217263 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed stage 3 CKD in US TriNetX database
Number of subjects: 20012
Study 37217262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare endoscopic mucosal resection (CS-EMR)
Number of subjects: 232
Study 37217262 — intervention group
Group type: COMPARATOR
Intervention: Hot snare endoscopic mucosal resection (HS-EMR)
Number of subjects: 232
Study 37217267 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-PRESTO rapid serological test
Number of subjects: 3228
Study 37217271 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection screening through PCR diagnosis
Number of subjects: 1000
Study 37217273 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS5315 4 or 2 mg once daily for 12 weeks
Number of subjects: 91
Study 37217273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 37217273 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS5315
Number of subjects: 91
Study 37217272 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI-RRT
Number of subjects: 0
Study 37217322 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care for weight management
Number of subjects: 57
Study 37217318 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate (VLC) diet
Number of subjects: 94
Study 37217318 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 94
Study 37217328 — intervention group
Group type: EXPERIMENTAL
Intervention: Three Good Things (3GT) digital intervention, 3 text messages per week asking for 3GT that occurred that day
Number of subjects: 223
Study 37217328 — intervention group
Group type: EXPERIMENTAL
Intervention: Three Good Things (3GT) digital intervention
Number of subjects: 223
Study 37217328 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 223
Study 37217440 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 3956
Study 37217511 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 93
Study 37217511 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 93
Study 37217511 — intervention group
Group type: COMPARATOR
Intervention: Control (Health Education)
Number of subjects: 93
Study 37217882 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure-guided ventilation (titration group)
Number of subjects: 53
Study 37217882 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 cmH2O driving pressure)
Number of subjects: 53
Study 37217885 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD/TPI plus irinotecan
Number of subjects: 28
Study 37217903 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (NCRT) followed by surgery
Number of subjects: 402
Study 37217903 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by surgery
Number of subjects: 402
Study 37217903 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 402
Study 37217911 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant insertion with internal connection implants (Twinfit, Dentaurum, Ispringen, Germany) after piezoelectric implant site preparation.
Number of subjects: 90
Study 37217960 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one motivational interviewing (MI) sessions in addition to standard in-person audiological care
Number of subjects: 0
Study 37217960 — intervention group
Group type: COMPARATOR
Intervention: Standard in-person audiological care
Number of subjects: 0
Study 37217980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim
Number of subjects: 5
Study 37218020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) for 8 weeks
Number of subjects: 23
Study 37218020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 23
Study 37218433 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation
Number of subjects: 0
Study 37218591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Blood Pressure Reduction (MB-BP)
Number of subjects: 201
Study 37218631 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB-based opioid-free anaesthesia (OFA group)
Number of subjects: 80
Study 37218631 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (control group)
Number of subjects: 80
Study 37218688 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion dysregulation in autistic females
Number of subjects: 74
Study 37218688 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion dysregulation in autistic males
Number of subjects: 74
Study 37218688 — intervention group
Group type: COMPARATOR
Intervention: Emotion dysregulation in females with borderline personality disorder
Number of subjects: 74
Study 37218946 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy guided by pre-RT Cho/NAA twice normal volume (Cho/NAA ≥ 2x)
Number of subjects: 0
Study 37219010 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney Preservation Strategies
Number of subjects: 0
Study 37219032 — intervention group
Group type: EXPERIMENTAL
Intervention: High AA/High Al-Anon involvement
Number of subjects: 279
Study 37219032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AA/Low Al-Anon involvement
Number of subjects: 279
Study 37219032 — intervention group
Group type: EXPERIMENTAL
Intervention: High AA/Low Al-Anon involvement
Number of subjects: 279
Study 37219032 — intervention group
Group type: EXPERIMENTAL
Intervention: High AA classes' COs
Number of subjects: 279
Study 37219032 — intervention group
Group type: EXPERIMENTAL
Intervention: COs' Al-Anon involvement
Number of subjects: 279
Study 37219072 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37219548 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based navigation intervention
Number of subjects: 225
Study 37219607 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute symptoms
Number of subjects: 425
Study 37219607 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent symptoms
Number of subjects: 425
Study 37219686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tovorafenib administered once every other day (Q2D) at RP2D of 200 mg
Number of subjects: 149
Study 37219686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tovorafenib administered once weekly (QW) at RP2D of 600 mg
Number of subjects: 149
Study 37219686 — intervention group
Group type: COMPARATOR
Intervention: Tovorafenib (both Q2D and QW)
Number of subjects: 149
Study 37219859 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF inhibitor (BRAFi) treatment
Number of subjects: 0
Study 37219859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual inhibition of BRAF and ERK1/2
Number of subjects: 0
Study 37219859 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of ERK1/2
Number of subjects: 0
Study 37219859 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion of fibronectin
Number of subjects: 0
Study 37219859 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous fibronectin
Number of subjects: 0